Findings

What do systematic reviews say?

1,497 questions · 1,590 findings · 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certainty Download CSV

No studies found 281 · 17.7%GRADE not reported 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Intervention not reported

Conception at > 12 months · patients with cervical intraepithelial lesions

It is very uncertain whether the intervention changes conception at > 12 months (very low certainty).

1 finding from 1 review

Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
RR 1.45 [0.89, 2.37]
3 studies · 1348 participants
Very low

Intervention not reported

Miscarriage rates · patients with cervical intraepithelial lesions

The intervention showed no clear difference in miscarriage rates (low certainty).

1 finding from 1 review

Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
RR 1.04 [0.9, 1.21]
10 studies · 39504 participants
Low

Intervention not reported

1st trimester miscarriage rates · patients with cervical intraepithelial lesions

The intervention showed no clear difference in 1st trimester miscarriage rates (low certainty).

1 finding from 1 review

Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
RR 1.16 [0.8, 1.69]
4 studies · 1103 participants
Low

Intervention not reported

2nd trimester miscarriage rates · patients with cervical intraepithelial lesions

The intervention may leads to higher 2nd trimester miscarriage rates (low certainty).

1 finding from 1 review

Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
RR 2.6 [1.45, 4.67]
8 studies · 2182268 participants
Low

Intervention not reported

Ectopic pregnancy · patients with cervical intraepithelial lesions

The intervention may leads to higher ectopic pregnancy (low certainty).

1 finding from 1 review

Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
RR 1.89 [1.5, 2.39]
6 studies · 38193 participants
Low

Intervention not reported

TOP rates · patients with cervical intraepithelial lesions

The intervention may leads to higher TOP rates (low certainty).

1 finding from 1 review

Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
RR 1.71 [1.31, 2.22]
7 studies · 38208 participants
Low

Cannabinoids vs placebo

Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of nausea ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2 [0.2, 21]
2 studies · 96 participants
Low

Cannabinoids vs other anti‐emetic agent

Participant preference · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher participant preference ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2.8 [1.9, 4]
9 studies · 799 participants
Low

Cannabinoids vs other anti‐emetic agent

Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher withdrawal any reason ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 3.5 [1.4, 9]
1 study · 42 participants
Low

Cannabinoids vs other anti‐emetic agent

Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoids changes withdrawal due to lack of efficacy ( compared with other anti‐emetic agent (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 0.97 [0.04, 21]
2 studies · 118 participants
Very low

Cannabinoids vs other anti‐emetic agent

Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher withdrawal due to adverse event ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 3.2 [1.3, 8]
6 studies · 740 participants
Low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 10 [0.61, 183]
1 study · 37 participants
Very low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.5 [0.69, 3.1]
2 studies · 89 participants
Low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.6 [0.68, 3.6]
1 study · 37 participants
Low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal any reason ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.3 [0.41, 4.2]
1 study · 41 participants
Low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 7 [0.88, 55]
2 studies · 105 participants
Very low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal due to lack of efficacy ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 0.12 [0.01, 2]
1 study · 41 participants
Low

Cannabinoids vs placebo

Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher absence of vomiting ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 5.7 [2.6, 12.6]
3 studies · 168 participants
Low

Cannabinoids vs placebo

Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids probably leads to higher absence of nausea and vomiting ( compared with placebo (moderate certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2.9 [1.8, 4.7]
3 studies · 288 participants
Moderate

Cannabinoids vs placebo

Participant preference · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher participant preference ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 4.8 [1.7, 13]
2 studies · 256 participants
Low